Ticker Update

CLASS 2 RECALL - Sodiofolin 50mg/ml Solution for Injection 100mg/2ml

Further to Drug Alert EL (20)A/52 issued on 11 November 2020, medac Pharma LLP is recalling further batches of products following inspection of vials showing hairline damage to the shoulder of the vials. So far, the company has not received any reports of damage for marketed products. However, as this defect may impact on the sterility of the product, the below batches are being recalled as a precautionary measure

MHRA Drug Link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medac-gmbh-t-slash-a-medac-pharma-llp-sodiofolin-50mg-slash-ml-solution-for-injection-100mg-slash-2ml-pl-11587-slash-0005-el-20-a-slash-61?utm_source=84015acc-7689-472c-92fe-db322a8d4537&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For more information or medical information queries, please contact info@medacpharma.co.uk or telephone 01786 458086.

Company-Led drug alert Sodium Chloride 0.9% Solution For Injection

Title:  Company-Led drug alert Sodium Chloride 0.9% Solution For Injection
Class type: Company-Led drug alert

Copy: Fresenius Kabi Ltd is recalling the below batch of Sodium chloride 0.9% Solution for injection (PL 08828/0178) which has a polish labelled ampoule within some of the cartons. As this does not impact the full batch, as a precautionary measure Fresenius Kabi are recalling all packs from this batch number. The outer carton is correct and includes the correct patient information leaflet in the English language. The ampoules are the correct composition and specifications as the UK licensed material, however during manufacture the incorrect ampoule label was used. The affected batch is being recalled and all stock will be replaced by corrected stock from Fresenius Kabi Limited.

The affected products' details are as follows:

Alliance do not stock this product we are not accepting stock returns.

For stock information enquiries, please contact: Fresenius Kabi Ltd customer services centre Email: Customer.Services-UK@Fresenius-Kabi.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Field Safety Notice - Voluntary Recall Unisex Patterned Sock C1 Med

L&R Medical Uk Ltd (Pway)is recalling the above batches of products as a Field Safety Notice - Voluntary Recall

The affected products' details are as follows:

This is a FSN voluntary recall and Alliance will be accepting stock returns.

For further information, please contact L&R Medical on 08450 606707

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

CLASS 2 RECALL - ZERBAXA 1G/0.5G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Merck Sharp & Dohme Limited is recalling the below batches due to the presence of Ralstonia pickettii in recent batches that were manufactured. The below batches are recalled as a precautionary measure whilst investigations into the microbiological quality of the distributed products are underway

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-merck-sharp-and-dohme-limited-zerbaxa-1g-slash-0-dot-5g-powder-for-concentrate-for-solution-for-infusion-el-20-a-slash-60?utm_source=22cd61e8-ab02-4646-bc21-a8c64c009886&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate     

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For stock control enquiries please contact customerservice.msduk@msd.com

Phone number: 01992 452094

For more information or medical information at medicalinformationuk@msd.com

Phone number: 01992 467272

Class 4 Drug Alert (Caution in use only) Co-Careldopa 25mg/100mg tablets

Fairmed Healthcare GmbH has informed us of a discrepancy on the product packaging for some batches. The discrepancy relates to the incorrect spelling of one of the active pharmaceutical ingredients printed on one side of the packs in error.

The affected products' details are as follows:

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact:

Fairmed Healthcare GmbH

Dorotheenstraße 48, 22301

Hamburg, Germany, Quality Assurance Department

or via email on QA Manager: l.rozikova@fair-med.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Class 4 Drug Alert (Caution in use only) Perindopril Erbumine 2mg, 4mg & 8mg Tablets

Generics [UK] Limited t/a Mylan have informed us that the Patient Information Leaflet (PIL) within the packs for the products listed above is missing relevant important safety information.

The affected products' details are as follows:

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Generics [UK] Limited t/a Mylan Medical Information Direct Line +44 (0)1707 853 000 select option 1, Customer Care direct line +44 (0)1707 853 000 select option 2 or via Medical Information e-mail info@mylan.co.uk

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

CLASS 2 RECALL - SIMVADOR 10, 20 & 40mg TABLETS

Lupin Healthcare (UK) Limited has informed us that the affected batches below (also distributed by Discovery Pharmaceuticals/Dexcel Pharma Limited) have been packaged with a version of patient information leaflet (PIL) that does not include the most up to date safety information..”   

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-lupin-healthcare-uk-limited-simvador-10mg-20mg-and-40mg-tablets-el-20-a-57?utm_source=22bc7d72-98a3-44b2-b529-22cffbe3f477&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate    

For stock control enquiries please contact +44 (0) 1565 751 378 Option 2 or information@lupin.com

For more information or medical information enquiries please contact +44 (0) 1565 751 378 Option 1 or

Pharmacovigilance Department at EU-PV@lupin.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

This recall will remain open for 3 months from the date issued unless an alternative date is agreed by instigator. The closure of this will be 04/03/2021. Please note after this date customer returns may still be accepted but customers may not be credited.

CLASS 2 RECALL - BETAHISTINE DIHYDROCHLORIDE 8MG & 16MG TABLETS

Kent Pharmaceuticals Ltd has informed us that the affected batches above are contaminated with theophylline due to a cross-contamination issue identified with an excipient that was used in the manufacture of the finished product. Therefore, a decision has been taken to recall the affected batches

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-kent-pharmaceuticals-ltd-betahistine-dihydrochloride-8mg-and-16mg-tablets-el-20-a-55?utm_source=40c23525-b2da-4a2b-9a24-fc70e06dce17&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For stock control enquiries please contact customer.service@kent-athlone.com

For more information or medical information medical@kent-athlone.com

Company Led - Caution in use - Epistatus

Dear Healthcare Professional,

We have been made aware of Midazolam Maleate (Epistatus 10mg in 1ml Oromucosal Solution, Multidose bottle), unlicensed, emergency use medication for prolonged, acute, convulsive seizures: Potential risk of faulty and incorrectly engaged child - resistant container closure 

Please click here for further information 

Suspected drug reactions may also be reported to Veriton Pharma Ltd, Telephone +44 (0)1932 690325

For reporting of identified defects or queries, please contact Vertion Pharma Ltd, Telephone +44 (0) 1932690325 or email info veritonpharma.com

CLASS 2 RECALL - LARGACTIL AMP 50MG/2ML

Sanofi is recalling the below batches due to out of specification results obtained for the impurity chlorpromazine sulphoxide, which was suspected to be caused by increased oxidation as a result of higher oxygen content in the headspace of the ampoules. As a precautionary measure, the above batches are being recalled.

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For stock control enquiries please contact GB-CustomerServices@sanofi.com or phone 0800 854 430

For medical information enquiries please contact uk-medicalinformation@sanofi.com or call 0800 035 25 25